Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
OrbiMed Advisors
AddedFeb 13, 2024
UpdatedJul 2, 2026
OrbiMed Advisors

OrbiMed Advisors

Operating

OrbiMed: A leading NYC-based investment firm specializing in healthcare and biotechnology sectors.

Location
New York City, NY, US
Founded
1989
Firm
Analysis
Compare
Portfolio
Employees
Website

OrbiMed Advisors is a prominent investment firm based in New York City, specializing in the healthcare and biotechnology sectors. The firm invests globally across various stages, including Series A, B, C, and beyond, as well as in private equity and venture capital. OrbiMed's investments typically range from early-stage ventures to late-stage companies, focusing on biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Notable portfolio companies include AbCellera Biologics, Adaptive Biotechnologies, and Caris Life Sciences. Key partners include Samuel Isaly, Michael Sheffery, and Arvind Desai. OrbiMed's investment philosophy centers on driving innovation and improving patient outcomes. The firm offers tailored financing solutions and leverages a global team to support portfolio companies. Unique value-add services include strategic guidance and access to a vast network of industry experts.

OrbiMed Advisors - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments244
Current Portfolio Count126
Total Portfolio Exits14

Top Investment Stages

Series A60 (31.4%)
Series B54 (28.3%)
Series C38 (19.9%)
Series Unknown23 (12.0%)
Post Ipo Equity16 (8.4%)

Stage Mix

Series A 31%Series B 28%Series C 20%Series Unknown 12%Post Ipo Equity 8%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Noctrix Health logo

Noctrix Health

OnCusp Therapeutics logo

OnCusp Therapeutics

Odyssey Therapeutics logo

Odyssey Therapeutics

Koya Medical logo

Koya Medical

Forward Therapeutics logo

Forward Therapeutics

Terremoto Biosciences logo

Terremoto Biosciences

Triveni Bio logo

Triveni Bio

Rampart Bioscience logo

Rampart Bioscience

AVITA Medical logo

AVITA Medical

Sirius Therapeutics logo

Sirius Therapeutics

Iambic Therapeutics logo

Iambic Therapeutics

Evozyne logo

Evozyne

Adela logo

Adela

ReCode Therapeutics logo

ReCode Therapeutics

Star Therapeutics logo

Star Therapeutics

Fore Biotherapeutics logo

Fore Biotherapeutics

Adarx Pharmaceuticals logo

Adarx Pharmaceuticals

Upstream Bio logo

Upstream Bio

Convergent Therapeutics logo

Convergent Therapeutics

Aer Therapeutics logo

Aer Therapeutics

TandemAI logo

TandemAI

Garuda Therapeutics logo

Garuda Therapeutics

Caris Life Sciences logo

Caris Life Sciences

Pathalys Pharma logo

Pathalys Pharma

Iecure logo

Iecure

OrbiMed Advisors - Similar Investment Firms

Orbit Venture Partners logo

Orbit Venture Partners

orbitvp.com

Global BioAccess Fund logo

Global BioAccess Fund

ORI Capital logo

ORI Capital

ori-capital.com

Orion Healthcare Equity Partners logo

Orion Healthcare Equity Partners

orhep.com

Orix Growth Capital logo

Orix Growth Capital

orix.com

Perceptive Advisors logo

Perceptive Advisors

perceptivelife.com

NaviMed Capital Advisors logo

NaviMed Capital Advisors

navimed.com

Deerfield Management logo

Deerfield Management

deerfield.com

Orlando Health Ventures logo

Orlando Health Ventures

orlandohealth.com

Petrichor Healthcare Capital Management logo

Petrichor Healthcare Capital Management

petrichorcap.com

Orbia Ventures logo

Orbia Ventures

orbia.com

Octagon Capital Advisors logo

Octagon Capital Advisors

Oryx Fund logo

Oryx Fund

oryxfund.com

Orchard Venture Partners logo

Orchard Venture Partners

Oryx Ventures logo

Oryx Ventures

oryxventures.com

OrbiMed Advisors - Classification

Also Known As
  • Orbimed Advisors Llc.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end